Cancer Drugs Approved for Reimbursement

As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy.

Alectinib

Alectinib

Apalutamide

Apalutamide

Asciminib

Atezolizumab

Atezolizumab

Atezolizumab  in combination with carboplatin and etoposide is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

In combination with nab-PACLitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease.

Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥5%.

As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.

Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) after prior platinum-containing chemotherapy.

Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.

Avelumab

First-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum based chemotherapy.

Axicabtagene ciloleucel

The treatment of adults with

•  Relapsed or refractory CD30 positive Hodgkin Lymphoma who have
  • failed at least one autologous stem cell transplant (ASCT) or
  •  at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
• Relapsed or refractory systemic anaplastic large cell lymphoma.

Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).

Treatment of adult patients with relapsed/refractory CD30+ Hodgkin’s lymphoma.

Treatment of adult patients with relapsed/refractory CD30+ Hodgkin’s lymphoma.

Daratumumab

Daratumumab

Daratumumab

Darolutamide

Durvalumab

Durvalumab 10mg/kg Monotherapy

Durvalumab 1500mg Monotherapy

As monotherapy for the treatment of adult patient with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,

• who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
• who have not received a prior NTRK inhibitor
• who have no satisfactory treatment options

For the treatment of disease-related splenomegaly or symptoms in adult patients with:

primary myelofibrosis (PMF)

post polycythaemia vera myelofibrosis (PVMF) or 

post essential thrombocythaemia myelofibrosis (ET MF) who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

Gemtuzumab ozogamicin

As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.

As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.

As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Idelalisib

Idelalisib with Ofatumumab

Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.

In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):

• who have received at least one prior therapy
  or
• as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies

In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):

• who have received at least one prior therapy
  or
• as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies

Ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,

• who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
• who have no satisfactory treatment options

For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,

• who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity,
• and who have no satisfactory treatment options

As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on

(i)   alectinib or ceritinib as the first ALK-targeted treatment

or

(ii) crizotinib and at least one other ALK-targeted treatment

Midostaurin is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.

For the treatment of disease-related splenomegaly or symptoms in adult patients with :

Moderate to severe anaemia who have primary myleofibrosis, 

Post polycythaemia vera myelofibrosis or

Post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

Nivolumab 240mg

Nivolumab 240mg

Nivolumab 480g

Nivolumab 240mg

Nivolumab 480mg

Nivolumab 280mg

Nivolumab 480g

As monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.

Nivolumab 240mg

Nivolumab 480mg

As monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.

Nivolumab 240mg 

Nivolumab 480mg

As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.

As monotherapy for the treatment of advanced renal cell carcinoma (RCC) after prior therapy in adults.

As monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.

In combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.

Nivolumab combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.

Nivolumab and ipilimumab plus PEMEtrexed and CISplatin therapy for the first-line treatment of metastatic non-squamous non-small cell lung
cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.

Nivolumab and ipilimumab plus PEMEtrexed and CARBOplatin therapy for the first-line treatment of metastatic non-squamous non-small cell lung
cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.

Nivolumab and ipilimumab plus CARBOplatin and PACLitaxel therapy for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.

Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate-/poor-risk advanced renal cell carcinoma.

Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.

Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.

Obinutuzumab maintenance therapy is indicated in patients with follicular lymphoma (FL) who have responded to induction treatment with obinutuzumab and bendamustine or have stable disease.

Obinutuzumab, in combination with chemotherapy, followed by maintenance treatment in patients achieving a response, for previously untreated advanced follicular lymphoma (FL).

In combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.

As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.

Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic)

high grade  epithelial ovarian cancer
fallopian tube cancer
primary peritoneal cancer
who are in response (complete response or partial response) following completion of first‐line platinum based chemotherapy.

As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA-mutated ovarian cancer (including fallopian tube or primary peritoneal) who are in response (complete response or partial response) to platinum-based chemotherapy.

As monotherapy for adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) whose tumour has epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.

Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.

Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy.

Pembrolizumab 200mg Monotherapy

For the adjuvant treatment of patients with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Pembrolizumab 200mg Monotherapy

For the adjuvant treatment of adults and adolescent (≥ 12 years of age) with stage IIB or IIC melanoma following complete resection.

Pembrolizumab 200mg Monotherapy

Pembrolizumab 400mg Monotherapy

June 2016

 ODMS

As monotherapy for the treatment of adults with unresectable or advanced melanoma.

For the treatment of ipilimumab-refractory patients with unresectable or advanced metastatic melanoma.

Pembrolizumab 200mg Monotherapy

Pembrolizumab 400mg Monotherapy

April 2018

ODMS

First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.

Pembrolizumab 200mg Monotherapy

Pembrolizumab 400mg Monotherapy

November 2018

ODMS

As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who are transplant-ineligible and have failed brentuximab vedotin.

Pembrolizumab

June 2024

ODMS

In combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.

Pembrolizumab

June 2023

ODMS

Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS≥10.

Pembrolizumab 200mg

Pembrolizumab 400mg

 April 2023

ODMS

 First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults.

Pembrolizumab 200mg Monotherapy

Pembrolizumab 400mg Monotherapy

 February 2022

ODMS

 As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.

Pembrolizumab 200mg

December 2021

ODMS

As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.

Pembrolizumab 400mg

December 2021

ODMS

As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.

Pembrolizumab

December 2021

ODMS

Pembrolizumab is indicated, in combination with CARBOplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.

Pembrolizumab

December 2021

ODMS

Pembrolizumab is indicated, in combination with CISplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.

Pembrolizumab 200mg

Pembrolizumab 400mg

 May 2021

ODMS

 As monotherapy for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection.

Pembrolizumab

February 2021

ODMS

In combination with pemetrexed and carboplatin chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.

Pembrolizumab

February 2021

ODMS

In combination with pemetrexed and cisplatin chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.

Pembrolizumab 200mg

Pembrolizumab 400mg

February 2021

ODMS

As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.

Pembrolizumab 200mg

Pembrolizumab 400mg

February 2021

ODMS

As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) ≥10.

Pembrolizumab

February 2021

ODMS

In combination with carboplatin and paclitaxel for the first-line treatment of patients with metastatic squamous Non-Small Cell Lung Cancer (NSCLC).

Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy.

In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist

Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.

The treatment of disease-related splenomegaly or symptoms in adult patients with:

• Primary myelofibrosis (chronic idiopathic myelofibrosis)
• Post polycythaemia vera myelofibrosis
• Post essential thrombocythaemia myelofibrosis

As monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Trastuzumab Deruxtecan

Treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.

Patients should have either:

• Received prior therapy for locally advanced or metastatic disease, or
• Developed disease recurrence during or within six months of completing adjuvant therapy

As a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.

Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.

Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.

Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.

Treatment of adult patients with Symptomatic metastatic basal cell carcinoma (MBCC).

Treatment of adult patients with Local advanced basal cell carcinoma inappropriate for surgery or radiotherapy.

Vxyeos liposomal® (DAUNOrubicin and cytarabine)

Induction Therapy

Consolidation Therapy

For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

 Zanubrutinib

As monotherapy

• for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who are treatment naïve and have del(17p) and/or TP53-mutated positive disease
• for the treatment of adult patients with chronic lymphocytic leukaemia with relapsed and/or refractory disease following at least one line of prior therapy

Zanubrutinib

For the treatment of for adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy, or as first-line treatment for patients unsuitable for chemo-immunotherapy.